A5065605420- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Acute Myeloid Leukemia Research
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Hepatocellular Carcinoma Treatment and Prognosis
- Economic and Financial Impacts of Cancer
- Neuroendocrine Tumor Research Advances
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pancreatitis Pathology and Treatment
- DNA Repair Mechanisms
- CAR-T cell therapy research
- Chromatin Remodeling and Cancer
- Cancer-related gene regulation
- Gallbladder and Bile Duct Disorders
- Gastrointestinal Tumor Research and Treatment
University of Cincinnati Medical Center
2020-2025
University of Cincinnati
2020-2025
The Ohio State University
2023
Cincinnati Health Department
2023
Cleveland Clinic
2013-2022
Tulane Medical Center
2021
Baylor College of Medicine
2021
Barrett Technology (United States)
2021
Cleveland Clinic Lerner College of Medicine
2014-2020
Eli Lilly (United States)
2010-2019
Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers children and adults. We evaluated the efficacy safety larotrectinib, a highly selective TRK inhibitor, adults who had tumors with these fusions.We enrolled patients consecutively prospectively identified fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into protocols: phase 1 study adults, 1-2 children, or 2 adolescents The primary end point for combined...
To develop an evidence-based clinical practice guideline to assist in decision making for patients with advanced hepatocellular carcinoma (HCC).
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations cancers of the liver, gallbladder, and bile ducts. Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data publications abstracts, reevaluate update recommendations. These Insights summarize panel's discussion most recent regarding locoregional therapy patients with hepatocellular carcinoma.
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations cancers of the liver, gallbladder, and bile ducts. Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data publications abstracts, reevaluate update recommendations. These Insights summarize panel’s discussion updated regarding systemic therapy first-line subsequent-line patients with hepatocellular carcinoma.
PURPOSE The aim of this work was to provide an update the ASCO guideline on metastatic pancreatic cancer pertaining recommendations for therapy options after first-line treatment. METHODS convened Expert Panel and conducted a systematic review second-line cancer. RESULTS One randomized controlled trial olaparib versus placebo, one report phase I II studies larotrectinib, entrectinib met inclusion criteria inform update. RECOMMENDATIONS New or updated germline somatic testing microsatellite...
Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential early control systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial.
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel 2). Measured parameters included resection rate, margin positivity, pathologic response, toxicity. Results: Between 2015 2018, 147 patients were randomized. Of these, 44 (30%) deemed ineligible (43 by...
Purpose: To broaden access to and implementation of precision medicine in the care patients with pancreatic cancer, Know Your Tumor (KYT) program was initiated using a turn-key system. Patients undergo commercially available multiomic profiling determine molecularly rationalized clinical trials off-label therapies.Experimental Design: samples were obtained for 640 from 287 academic community practices covering 44 states. College American Pathologists/Clinical Laboratory Improvement...
KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal adenocarcinoma (PDAC). A small subset of PDACs harbor wild-type (WT). We aim to characterize the molecular profiles WT PDAC uncover new pathogenic drivers and offer targeted treatments.
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the and safety of larotrectinib in patients thyroid carcinoma (TC).We pooled data from three phase I/II clinical trials (NCT02576431, NCT02122913, NCT02637687). The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria Solid Tumors v1.1. Secondary endpoints included duration...
To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) patients considered immune checkpoint inhibitor therapy. ASCO policy set procedures endorsing clinical practice guidelines that have been by other professional organizations.The CAP was reviewed developmental rigor methodologists. An Endorsement Panel subsequently the content recommendations.The determined recommendations from guideline, published...
Even though pancreatic ductal adenocarcinoma (PDAC) is associated with fibrotic stroma, the molecular pathways regulating formation of cancer fibroblasts (CAFs) are not well elucidated. An epigenomic analysis patient-derived and de-novo generated CAFs demonstrated widespread loss cytosine methylation that was overexpression various inflammatory transcripts including CXCR4. Co-culture neoplastic cells led to increased invasiveness abrogated by inhibition Metabolite tracing revealed lactate...
Although a combination of genomic and epigenetic alterations are implicated in the multistep transformation normal squamous esophageal epithelium to Barrett esophagus, dysplasia, adenocarcinoma, combinatorial effect these changes is unknown. By integrating genome-wide DNA methylation, copy number, transcriptomic datasets obtained from endoscopic biopsies neoplastic progression within same individual, we uniquely able define molecular events associated esophagus. We find that previously...
Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated. We previously shown myelosuppressive TGF-β pathway is constitutively activated in MDS progenitors. Because there conflicting data about upregulation of extracellular levels MDS, we wanted determine basis overactivation and consequent hematopoietic suppression this disease. observed SMAD7, a negative regulator receptor...
4504 Background: Clinical outcomes after curative treatment of resectable PDA remain suboptimal. To assess the potential early control systemic disease with multiagent peri-op CTx, we conducted a prospective trial in National Trials Network. Methods: S1505 was randomized phase II CTx (12 weeks pre-, 12 post-op) either mFOLFIRINOX (Arm 1) or Gem/nabP 2). Eligibility required confirmed tissue diagnosis PDA, ECOG PS 0 1, and per Intergroup criteria. Primary outcome 2-year overall survival (OS),...
Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age 18 years or older, Eastern Cooperative Oncology Group performance status 0–2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results reviewed Clinic Genomics Tumor Board. Outcomes included feasibility impact....